Persistently high IgA serum levels are a marker of immunological or virological failure of combined antiretroviral therapy in children with perinatal HIV-1 infection

Clinical and Experimental Immunology

Volumn 140, Issue 2, 2005, Pages 320-324

  De Martino, Maurizio ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Combinedantiretroviral therapy; HIV 1 infection; Hyper IgA

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGY; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PERINATAL INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; DRUG MONITORING; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN A; INFANT; INFANT, NEWBORN; TREATMENT FAILURE; VIRAL LOAD;

EID: 17644408106     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02756.x     Document Type: Article

References (29)

1. Chinen J, Shearer WT. Molecular virology and immunology of HIV infection. J Allergy Clin Immunol 2002; 110:189-98.
2. de Martino M, Tovo PA, Galli L et al. Prognostic significance of immunologic changes in 675 infants perinatally exposed to human immunodeficiency virus. The Italian Register for Human Immunodeficiency Virus Infection in Children. J Pediatr 1991; 119:702-9.
3. Shearer WT, Easley KA, Goldfarb J et al. The P(2)C(2) HIV Study Group. Prospective 5-year study of peripheral blood CD4, CD8, and CD19/CD20 lymphocytes and serum Igs in children born to HIV-1 women. J Allergy Clin Immunol 2000; 106:559-66.
4. Betensky RA, Calvelli T, Pahwa S. Predictive value of CD19 measurements for bacterial infections in children infected with human immunodeficiency virus. Clin Diagn Laboratory Immunol 1999; 6:247-53.
5. Shearer WT, Easley KA, Goldfarb J et al. The P(2)C(2) HIV Study Group. Evaluation of immune survival factors in pediatric HIV-1 infection. Ann NY Acad Sci 2000; 918:298-312.
6. Jacobson MA, Khayam-Bashi H, Martin JN, Black D, Ng V. Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. J Acquir Immune Defic Syndr 2002; 31:472-7.
7. Notermans DW, de Jong JJ, Goudsmit J et al. Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses 2001; 17:1003-8.
8. Morris L, Binley JM, Clas BA et al. HIV-1 antigen-specific and - nonspecific B cell responses are sensitive to combined antiretroviral therapy. J Exp Med 1998; 188:233-45.
9. Fournier AM, Baillat V, Alix-Panabieres C et al. Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. AIDS 2002; 16:1755-60.
10. Lugada ES, Mermin J, Asjio B et al. Immunoglobulin levels amongst persons with and without human immunodeficiency virus type 1 infection in Uganda and Norway. Scand J Immunol 2004; 59:203-8.
11. de Martino M, Tovo PA, Balducci M et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. J Am Med Assoc 2000; 284:190-7.
12. Tovo PA, de Martino M, Gabiano C et al. Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections Children. Lancet 1992; 339:1249-53.
13. Centers for Disease Control and Prevention 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morb Mortal Wkly Rep 1994; 43 (RR-12):1-10.
14. The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children convened by the National Pediatric and Family HIV Resource Center (NPHRC), The Health Resources and Services Administration (HRSA), and The. National Institutes of Health (NIH). (2003) Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. [WWW document]. URL http://aidsinfo.nih.gov (accessed 25 June 2003)
15. Centers for Disease Control and Prevention. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Morb Mortal Wkly Rep 1998; 47 (RR-4):1-43.
16. Italian Register for Human Immunodeficiency Virus Infection in Children. Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. Acta Paediatr 1999; 88:228-32.
17. Peruzzi M, Azzari C, Galli L, Vierucci A, de Martino M. Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virologic failure. Clin Exp Immunol 2002; 128:365-71.
18. Katzenstein TL, Ullum H, Roge BT, Wandall J, Dickmeiss E, Barrington T, Skinhoj P, Gerstoft J. Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months. HIV Med 2003; 4:53-61.
19. Lange M, Maitra US, Klein EB, Inada Y, Taskar V, Sundar K. Triple combination antiretroviral therapy improves some but not all predictive surrogate markers in HIV infected patients. Conf Retroviruses Opportunistic Infect 1997; 110: (abstract no. 249a).
20. McIntyre TM, Kehry MR, Snapper CM. Novel in vitro model for high-rate IgA class switching. J Immunol 1995; 154:3156-61.
21. Zan H, Cerutti A, Dramitinos P, Schaffer A, Casali P. CD40 engagement triggers switching to IgA1 and IgA2 in human B cells through induction of endogenous TGF-β: evidence for TGF-β but not IL-10-dependent direct Sμ→α and sequential Sμ→Sγ, Sγ→α DNA recombination. J Immunol 1998; 161:5217-25.
22. Sonoda E, Hitoshi Y, Yamaguchi N, Ishii T, Tominaga A, Araki S, Takatsu K. Differential regulation of IgA production by TGF-beta and IL-5: TGF-beta induces surface IgA-positive cells bearing IL-5 receptor, whereas IL-5 promotes their survival and maturation into IgA-secreting cells. Cell Immunol 1992; 140:158-72.
23. O'Gorman MR, DuChateau B, Paniagua M, Hunt J, Bensen N, Yogev R. Abnormal CD40 ligand (CD154) expression in human immunodeficiency virus-infected children. Clin Diagn Laboratory Immunol 2001; 8:1104-9.
24. Hu R, Oyaizu N, Than S, Kalyanaraman VS, Wang XP, Pahwa S. HIV-1 gp160 induces transforming growth factor-beta production in human PBMC. Clin Immunol Immunopathol 1996; 80:283-9.
25. Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D. Increased Plasma Transforming Growth Factor-beta (1) Is Associated with Disease Progression in HIV-1-Infected Patients. Viral Immunol 2004; 17:109-13.
26. de Martino M, Rossi ME, Azzari C, Chiarelli F, Galli L, Vierucci A. Interleukin-6 synthesis and IgE overproduction in children with perinatal human immunodeficiency virus-type 1 infection. Ann Allergy Asthma Immunol 1999; 82:212-6.
27. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997; 98:187-228.
28. Kent DM, McGrath D, Ioannidis JP, Bennish ML. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin Infect Dis 2003; 37:S13-24.
29. Mofenson LM, Harris DR, Moye J, Bethel J, Korelitz J, Read JS, Nugent R, Meyer W, for the NICHD IVIG Clinical Trial Study Group. Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings. Lancet 2003; 362:1625-7.